Navigation Links
Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
Date:4/2/2008

AMSTERDAM, The Netherlands, April 2 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that AMT's Supervisory Board has decided to propose Dr. George Morstyn to be appointed to the Supervisory Board at its Annual General Meeting of shareholders on April 16, 2008. Dr. Morstyn (MB BS PhD FRACP), who retired as Senior Vice President of Development at Amgen, was a member of Amgen's executive committee and responsible for global preclinical and clinical development as well as regulatory affairs.

Dr. Morstyn also played an active role in representing Amgen to the financial community. Five new drugs and many label extensions were approved during his 11 year tenure. Dr. Morstyn graduated from Monash University, completed a Ph.D. with Professor Donald Metcalf at the Walter and Eliza Hall Institute and trained in medical oncology at the National Cancer Institute in the US. He was Head of the Clinical Program of the Ludwig Institute for Cancer Research in Melbourne for eight years. Dr. Morstyn was an early clinical investigator of several biological agents prior to joining Amgen, and performed seminal work on the development of G-CSF, which later became Neupogen, Amgen's second blockbuster drug. Dr. Morstyn is currently a board member of several Australian biotechnology companies.

Further to a plan of rotation, AMT aims to build a fully independent Supervisory Board in the course of 2008. Earlier this year, AMT announced the nominations of Alexander Ribbink, COO of TomTom, and Philippe van Holle, Head of Celgene Europe, to its Supervisory Board.

AMT's AGM is scheduled for April 16, 10:30 a.m., and will take place at the Rosarium, Amsterdam, The Netherlands.

About Amsterdam Molecular Therapeutics

AMT has a unique gene therapy platform that to date appears to circumvent many if not all of the obstacles that have prevented gene therapy from becoming a ma
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
3. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
4. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Sigma-Aldrich Partners With Sunset Molecular Discovery to Expand Your Favorite Gene Search Tool
7. Vicus Therapeutics Announces Participation at 15th International Molecular Medicine Tri-Conference
8. Society for Biomolecular Sciences Announces 2008 Conference Speaker Line-up
9. WaferGen to Present at the Cambridge Health Institutes Fifth Annual Molecular Diagnostics Partnerships in Personalized Medicine Conference
10. NIST team proves bridge from conventional to molecular electronics possible
11. AcroMetrix Signs Development and Supply Agreement With Beckman Coulter Inc. for Molecular Quality Control Standards

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...,Nov.24/PRNewswire-FirstCall/--DowAgroSciencesCana...s,adivisionofThompsonsLimitedofBlenheim,Ontario.Th...nces,currentseedsbusinessasthecompanyanticipatesth...SciencesHerbicideTolerantTraitTechnologyincornin20... ,, "Thisacquisitionbringstogethertwostrongprog...
(Date:11/24/2009)...-Asia/--NODPharmaceuticalsInc.announced,theUSPaten...cationfor,itsnano-particleoraldeliveryorNODtechnol...htoincorporatepeptidesor,proteinsintobio-adhesiven...administeredasinjections.NODtechnologyisaplatformt...ssuchasinsulin,interferon,growthhormone,exenatide...
(Date:11/24/2009)...beenmetforpatientswithadvanced-stage,orrecurrenten...re-FirstCall/-AEternaZentarisInc.(NASDAQ: AEZS ;TS...nyfocusedonendocrinetherapyandoncology,todayannoun...etedcytotoxicpeptideconjugate,AEZS-108(formerlyAN-...ancer.Inapersonalizedhealthcareapproach,thestudyse...
(Date:11/24/2009)...ewswire/--HealthRoboticstodayannounced,thatithasfo...nvestors.ThisrecentlyformedToronto-basedcompanywil...illmarket,install,andsupport,HealthRobotics,i.v.Ro...yproductofferingsi.v.STATION(TM),i.v.SOFT(TM),andO...istanceonan"asneeded,basis"toitsstrategicpartnersh...
Breaking Biology Technology:Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2
...h Park MADISON OpGen, Inc. has added two new me...omas Pyle. The company is looking to bring in seas...he next level, according to Dan Broderick, managin... , ,They bring lots of experience with company ope...hey have long, successful careers in business and ...
...y figures show no reported venture investment acti...ear. Both total venture capital and initial ventur...as released by PricewaterhouseCoopers, Thomson Ven...sociation. Ten other states also showed $0 activit...money, according to the survey, with California re...
...ializing in patient-specific molecular data and pe...ts president and chief executive officer, it annou...esident and CEO of Pel-Freez Clinical Systems , l...ar biology and serologic products for solid organ ...icant growth and eventual acquisition under Langel...
Other Biology Technology:OpGen adds Thomas Pyle and James Ogle to board of directors 2MoneyTree Survey reports no venture investment activity in Wisconin in Q2 2MoneyTree Survey reports no venture investment activity in Wisconin in Q2 3MoneyTree Survey reports no venture investment activity in Wisconin in Q2 4MoneyTree Survey reports no venture investment activity in Wisconin in Q2 5MoneyTree Survey reports no venture investment activity in Wisconin in Q2 6
(Date:11/24/2009)... atomic-level action of a remarkable class of ring...rchers with the Lawrence Berkeley National Laborat...n crystallography beamline at the Advanced Light S...es in gene expression and replication, and are vit...l as infectious agents, such as the human papillom...
(Date:11/24/2009)...at constitutes fish food is a matter of debate. A ...fish get almost 50 percent of their carbon from tr...ween the terrestrial and aquatic ecosystems. , B...shows this is not likely to be true. Algae provide...e, according to research published this week in th...
(Date:11/23/2009)...hington, D.C. The community-associated strain of ...ria resistant to most common antibioticsposes a fa...is making its way into hospitals, according to a s... Diseases . , The new threat is easily picked u...aces and has increased the overall burden of MRSA ...
Breaking Biology News(10 mins):Atomic-level snapshot catches protein motor in action 2Atomic-level snapshot catches protein motor in action 3Atomic-level snapshot catches protein motor in action 4Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3New study finds MRSA on the rise in hospital outpatients 2IBM Analytics Expands To Help Governments Around World Build Smarter Systems 54203 1IBM Analytics Expands To Help Governments Around World Build Smarter Systems 54203 2IBM Analytics Expands To Help Governments Around World Build Smarter Systems 54203 3IBM Analytics Expands To Help Governments Around World Build Smarter Systems 54203 4Plasma Protein Therapeutics Association Urges CMS For Appropriate Hospital Outpatient Drug Reimbursement 54200 1Plasma Protein Therapeutics Association Urges CMS For Appropriate Hospital Outpatient Drug Reimbursement 54200 2Plasma Protein Therapeutics Association Urges CMS For Appropriate Hospital Outpatient Drug Reimbursement 54200 3BP and Martek Biosciences Enter Joint Development Agreement to Deliver Advanced Biodiesels 13502 1BP and Martek Biosciences Enter Joint Development Agreement to Deliver Advanced Biodiesels 13502 2BP and Martek Biosciences Enter Joint Development Agreement to Deliver Advanced Biodiesels 13502 3BP and Martek Biosciences Enter Joint Development Agreement to Deliver Advanced Biodiesels 13502 4
...T LAFAYETTE, Ind. - Chemical engineers have develo...an inexpensive way of making diamondlike crystals ...logies. , The method, developed at Purdue Univers...licon template containing precisely spaced holes t...air. The template is immersed in water on top of w...
...orld was in shock when in 2001 the Talibans destro...han region of Bamiyan. Behind those statues, there...5th to 9th century A.D. The caves also suffered fr...atural environment, but today they have become the...ed, thanks to experiments performed at the Europea...
...er twenty-five years of investigating, analyzing, ...ers, neighbors, and even surviving victims, crimin...of the worlds most respected experts on the motiva...n SERIAL KILLERS AND SADISTIC MURDERERS: UP CLOSE ...is wealth of experience with the criminal mind to ...
Other Biology News:Findings a step toward making new optical materials 2Findings a step toward making new optical materials 3Findings a step toward making new optical materials 4Findings a step toward making new optical materials 5Synchrotron light unveils oil in ancient Buddhist paintings from Bamiyan 2A chilling glimpse inside the minds of dangerous criminals 2
Alkaline Phosphatase (E. coli C75) from GE Healthcare, formerly Amersham Biosciences
...and cDNA Labeling Kit with CyScribe GFX Purificati...ication of Cy3- and Cy5-labeled cDNA.Optimized rea...ling and purification.Flexible and optimized proto... with either Cy3- or Cy5-labeled nucleotides.Relia...
...ling Kit with CyScribe GFX Purification Kit, 24 re...3- and Cy5-labeled cDNA.Optimized reagents are pac...fication.Flexible and optimized protocols can be u...Cy3- or Cy5-labeled nucleotides.Reliable purificat...
Canine serum from Equitech-Bio
Biology Products: